File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment

TitleQuantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment
Authors
Issue Date2011
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html
Citation
American Journal Of Gastroenterology, 2011, v. 106 n. 10, p. 1766-1773 How to Cite?
AbstractObjectives: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response in chronic hepatitis B patients treated with entecavir 0.5 mg daily for 2 years. Methods: A total of 166 patients were included. Liver biochemistry, hepatitis B virus (HBV) serological markers, HBV DNA, and quantitative HBsAg levels were performed at baseline, year 1, and year 2 after commencing entecavir. Additional HBsAg levels were measured at 12 and 24 weeks in patients with available sera. Results: In all, 68 patients were hepatitis B e-antigen (HBeAg) positive. Age, HBV DNA, and alanine aminotransferase (ALT) were significantly correlated with HBsAg levels at baseline (r=-0.429, 0.607, and 0.254, respectively, all P<0.05). The correlation with HBV DNA and ALT levels was reduced by entecavir treatment, and was lost after 2 years of treatment. There was an overall decline in HBsAg levels from baseline to year 1 to year 2 (3,377.4 vs. 2,316.5 vs. 1,903.0 IU/ml, respectively, P<0.001). However, at year 2, 102 patients (61%) had no significant changes (<0.5 log difference), 50 (30%) had significant decline (≥0.5 log decrease), whereas 14 (9%) had significant increase (0.5 log increase). Of the patients, 151 (91%) had undetectable HBV DNA; 25 (37%) underwent HBeAg seroconversion. Neither HBsAg at baseline nor early decline at weeks 12 or 24 was predictive of HBeAg seroconversion at 2 years. Conclusions: Despite HBV DNA suppression, the majority did not show significant decline in HBsAg levels. Early decline of HBsAg levels at 12/24 weeks was not associated with HBV DNA suppression or HBeAg seroconversion. © 2011 by the American College of Gastroenterology.
Persistent Identifierhttp://hdl.handle.net/10722/142389
ISSN
2014 Impact Factor: 10.755
2014 SCImago Journal Rankings: 3.376
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorYoung, Jen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorYuen, Jen_HK
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorYuen, MFen_HK
dc.date.accessioned2011-10-28T02:44:56Z-
dc.date.available2011-10-28T02:44:56Z-
dc.date.issued2011en_HK
dc.identifier.citationAmerican Journal Of Gastroenterology, 2011, v. 106 n. 10, p. 1766-1773en_HK
dc.identifier.issn0002-9270en_HK
dc.identifier.urihttp://hdl.handle.net/10722/142389-
dc.description.abstractObjectives: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response in chronic hepatitis B patients treated with entecavir 0.5 mg daily for 2 years. Methods: A total of 166 patients were included. Liver biochemistry, hepatitis B virus (HBV) serological markers, HBV DNA, and quantitative HBsAg levels were performed at baseline, year 1, and year 2 after commencing entecavir. Additional HBsAg levels were measured at 12 and 24 weeks in patients with available sera. Results: In all, 68 patients were hepatitis B e-antigen (HBeAg) positive. Age, HBV DNA, and alanine aminotransferase (ALT) were significantly correlated with HBsAg levels at baseline (r=-0.429, 0.607, and 0.254, respectively, all P<0.05). The correlation with HBV DNA and ALT levels was reduced by entecavir treatment, and was lost after 2 years of treatment. There was an overall decline in HBsAg levels from baseline to year 1 to year 2 (3,377.4 vs. 2,316.5 vs. 1,903.0 IU/ml, respectively, P<0.001). However, at year 2, 102 patients (61%) had no significant changes (<0.5 log difference), 50 (30%) had significant decline (≥0.5 log decrease), whereas 14 (9%) had significant increase (0.5 log increase). Of the patients, 151 (91%) had undetectable HBV DNA; 25 (37%) underwent HBeAg seroconversion. Neither HBsAg at baseline nor early decline at weeks 12 or 24 was predictive of HBeAg seroconversion at 2 years. Conclusions: Despite HBV DNA suppression, the majority did not show significant decline in HBsAg levels. Early decline of HBsAg levels at 12/24 weeks was not associated with HBV DNA suppression or HBeAg seroconversion. © 2011 by the American College of Gastroenterology.en_HK
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.htmlen_HK
dc.relation.ispartofAmerican Journal of Gastroenterologyen_HK
dc.subject.meshAntiviral Agents - administration and dosage - therapeutic use-
dc.subject.meshGuanine - administration and dosage - analogs and derivatives - therapeutic use-
dc.subject.meshHepatitis B Surface Antigens - blood-
dc.subject.meshHepatitis B virus - genetics - immunology - isolation and purification-
dc.subject.meshHepatitis B, Chronic - drug therapy - enzymology - immunology-
dc.titleQuantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatmenten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0002-9270&volume=106&issue=10&spage=1766&epage=1773&date=2011&atitle=Quantitative+Hepatitis+B+Surface+Antigen+Levels+in+Patients+With+Chronic+Hepatitis+B+After+2+Years+of+Entecavir+Treatmenten_US
dc.identifier.emailFung, J: jfung@sicklehut.comen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailSeto, WK: wkseto2@hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.authorityFung, J=rp00518en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/ajg.2011.253en_HK
dc.identifier.pmid21826112en_HK
dc.identifier.scopuseid_2-s2.0-80053894414en_HK
dc.identifier.hkuros196659en_US
dc.identifier.hkuros213672-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80053894414&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume106en_HK
dc.identifier.issue10en_HK
dc.identifier.spage1766en_HK
dc.identifier.epage1773en_HK
dc.identifier.isiWOS:000295926600005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridFung, J=23091109300en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridYoung, J=16949957200en_HK
dc.identifier.scopusauthoridWong, DKH=7401535819en_HK
dc.identifier.scopusauthoridYuen, J=7102620480en_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats